Catalyst overview
Research summary
This catalyst tracks a Phase 3 initiation for BIIB080 (tau ASO) in Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
Ph2 CEILA study currently ongoing. New Ph1b data and Ph2 Trial presentation at CTAD '23. 05/14/26:- Ph2 CELIA topline results showed tau reductions and cognitive slowing. Data to be presented at AAIC 2026. 06/29/26:- Present Ph2 CELIA clinical, biomarker, and safety data at AAIC 2026 on July 14, 2026. 07/14/26:- Phase 2 CELIA data at AAIC 2026; primary endpoint missed; plans to advance into Phase 3.
Verification
Confirm timing and program details against the company announcement or filing.